BARKLEY WHNP DIAGNOSTIC READINESS EXAM REVIEW 2026/2027
| HIGH-YIELD QUESTIONS & ANSWERS | KEY WOMEN’S HEALTH
CLINICAL CONCEPTS | EXAM-STYLE PRACTICE | DETAILED
RATIONALES | LATEST UPDATE
SECTION 1: WELL-WOMAN GYNECOLOGY & PREVENTIVE CARE
(Questions 1-40)
Question 1
1. A 22-year-old woman presents for her first Pap test. According to current ASCCP guidelines,
cervical cancer screening with cytology alone should begin at age:
A) 18
B) 21
C) 25
D) 30
Answer
Answer B: . 21
Rationale
The American Society for Colposcopy and Cervical Pathology (ASCCP) and USPSTF recommend
initiating cervical cancer screening at age 21, regardless of sexual history. Screening before age 21 is
not recommended due to the low incidence of cervical cancer and the high likelihood of transient HPV
infections that resolve spontaneously. ---
Question 2
2. A 30-year-old woman has a Pap test with HPV co-testing. The result is negative for
intraepithelial lesion or malignancy (NILM) and HPV negative. The recommended follow-up is:
A) Repeat co-testing in 1 year
B) Repeat co-testing in 3 years
C) Repeat co-testing in 5 years
D) Colposcopy
Answer
,Answer C: . Repeat co-testing in 5 years
Rationale
For women aged 30-65 with a negative co-test (NILM and HPV negative), routine screening is
recommended no sooner than every 5 years. This extended interval is safe due to the low risk of
cervical cancer in HPV-negative women. ---
Question 3
3. Which of the following is a known risk factor for cervical cancer?
A) Multiparity
B) Persistent infection with high-risk HPV types 16 and 18
C) Early menopause
D) Endometriosis
Answer
Answer B: . Persistent infection with high-risk HPV types 16 and 18
Rationale
Persistent infection with oncogenic (high-risk) HPV types, especially 16 and 18, is the primary cause of
cervical cancer. HPV 16 and 18 are responsible for approximately 70% of cervical cancers worldwide.
---
Question 4
4. The quadrivalent HPV vaccine (Gardasil) protects against which HPV types?
A) 6, 11, 16, 18
B) 16, 18, 31, 33
C) 31, 33, 45, 52
D) 6, 11, 16, 18, 31, 33, 45, 52, 58
Answer
Answer A: . 6, 11, 16, 18
Rationale
,The quadrivalent vaccine covers HPV 6 and 11 (low-risk types that cause approximately 90% of
genital warts) and HPV 16 and 18 (high-risk types that cause approximately 70% of cervical cancers).
The 9-valent vaccine (Gardasil 9) covers additional high-risk types. ---
Question 5
5. A 45-year-old woman reports irregular, heavy menses and hot flashes. Her FSH level is
elevated. Which phase of reproductive aging is she most likely experiencing?
A) Premenopause
B) Perimenopause (menopause transition)
C) Postmenopause
D) Primary ovarian insufficiency
Answer
Answer B: . Perimenopause (menopause transition)
Rationale
The menopause transition (perimenopause) is characterized by menstrual cycle irregularity, vasomotor
symptoms, and elevated FSH levels, typically occurring in the mid- to late 40s. Perimenopause begins
with the onset of menstrual irregularity and ends 12 months after the final menstrual period. ---
Question 6
6. The most common cause of secondary amenorrhea in a reproductive-age woman after
pregnancy has been ruled out is:
A) Asherman's syndrome
B) Polycystic ovary syndrome (PCOS)
C) Hypothalamic amenorrhea
D) Premature ovarian failure
Answer
Answer B: . Polycystic ovary syndrome (PCOS)
Rationale
PCOS is the most common endocrine cause of secondary amenorrhea. It is characterized by chronic
anovulation, hyperandrogenism, and polycystic ovarian morphology. Hypothalamic amenorrhea
(functional) is also common but PCOS is the leading overall cause. ---
, Question 7
7. A 27-year-old woman with PCOS is seeking contraception. Which method also addresses her
underlying hyperandrogenism and menstrual irregularity?
A) Copper IUD
B) Combined oral contraceptives (COCs)
C) Progestin-only pill
D) Condoms
Answer
Answer B: . Combined oral contraceptives (COCs)
Rationale
COCs suppress ovarian androgen production and increase sex hormone-binding globulin (SHBG),
reducing free testosterone. They also regulate menstrual cycles and provide contraceptive benefits,
making them first-line therapy for PCOS when pregnancy is not desired. ---
Question 8
8. A 52-year-old woman complains of vulvovaginal dryness, dyspareunia, and urinary urgency.
She is not interested in systemic hormone therapy. What is the most appropriate first-line
treatment for her genitourinary syndrome of menopause?
A) Oral ospemifene
B) Vaginal estrogen therapy
C) Systemic estrogen-progestin therapy
D) Testosterone gel
Answer
Answer B: . Vaginal estrogen therapy
Rationale
Low-dose vaginal estrogen is the most effective treatment for moderate-to-severe genitourinary
syndrome of menopause (GSM). It has minimal systemic absorption and is safe for women who
cannot or choose not to use systemic hormone therapy. ---
| HIGH-YIELD QUESTIONS & ANSWERS | KEY WOMEN’S HEALTH
CLINICAL CONCEPTS | EXAM-STYLE PRACTICE | DETAILED
RATIONALES | LATEST UPDATE
SECTION 1: WELL-WOMAN GYNECOLOGY & PREVENTIVE CARE
(Questions 1-40)
Question 1
1. A 22-year-old woman presents for her first Pap test. According to current ASCCP guidelines,
cervical cancer screening with cytology alone should begin at age:
A) 18
B) 21
C) 25
D) 30
Answer
Answer B: . 21
Rationale
The American Society for Colposcopy and Cervical Pathology (ASCCP) and USPSTF recommend
initiating cervical cancer screening at age 21, regardless of sexual history. Screening before age 21 is
not recommended due to the low incidence of cervical cancer and the high likelihood of transient HPV
infections that resolve spontaneously. ---
Question 2
2. A 30-year-old woman has a Pap test with HPV co-testing. The result is negative for
intraepithelial lesion or malignancy (NILM) and HPV negative. The recommended follow-up is:
A) Repeat co-testing in 1 year
B) Repeat co-testing in 3 years
C) Repeat co-testing in 5 years
D) Colposcopy
Answer
,Answer C: . Repeat co-testing in 5 years
Rationale
For women aged 30-65 with a negative co-test (NILM and HPV negative), routine screening is
recommended no sooner than every 5 years. This extended interval is safe due to the low risk of
cervical cancer in HPV-negative women. ---
Question 3
3. Which of the following is a known risk factor for cervical cancer?
A) Multiparity
B) Persistent infection with high-risk HPV types 16 and 18
C) Early menopause
D) Endometriosis
Answer
Answer B: . Persistent infection with high-risk HPV types 16 and 18
Rationale
Persistent infection with oncogenic (high-risk) HPV types, especially 16 and 18, is the primary cause of
cervical cancer. HPV 16 and 18 are responsible for approximately 70% of cervical cancers worldwide.
---
Question 4
4. The quadrivalent HPV vaccine (Gardasil) protects against which HPV types?
A) 6, 11, 16, 18
B) 16, 18, 31, 33
C) 31, 33, 45, 52
D) 6, 11, 16, 18, 31, 33, 45, 52, 58
Answer
Answer A: . 6, 11, 16, 18
Rationale
,The quadrivalent vaccine covers HPV 6 and 11 (low-risk types that cause approximately 90% of
genital warts) and HPV 16 and 18 (high-risk types that cause approximately 70% of cervical cancers).
The 9-valent vaccine (Gardasil 9) covers additional high-risk types. ---
Question 5
5. A 45-year-old woman reports irregular, heavy menses and hot flashes. Her FSH level is
elevated. Which phase of reproductive aging is she most likely experiencing?
A) Premenopause
B) Perimenopause (menopause transition)
C) Postmenopause
D) Primary ovarian insufficiency
Answer
Answer B: . Perimenopause (menopause transition)
Rationale
The menopause transition (perimenopause) is characterized by menstrual cycle irregularity, vasomotor
symptoms, and elevated FSH levels, typically occurring in the mid- to late 40s. Perimenopause begins
with the onset of menstrual irregularity and ends 12 months after the final menstrual period. ---
Question 6
6. The most common cause of secondary amenorrhea in a reproductive-age woman after
pregnancy has been ruled out is:
A) Asherman's syndrome
B) Polycystic ovary syndrome (PCOS)
C) Hypothalamic amenorrhea
D) Premature ovarian failure
Answer
Answer B: . Polycystic ovary syndrome (PCOS)
Rationale
PCOS is the most common endocrine cause of secondary amenorrhea. It is characterized by chronic
anovulation, hyperandrogenism, and polycystic ovarian morphology. Hypothalamic amenorrhea
(functional) is also common but PCOS is the leading overall cause. ---
, Question 7
7. A 27-year-old woman with PCOS is seeking contraception. Which method also addresses her
underlying hyperandrogenism and menstrual irregularity?
A) Copper IUD
B) Combined oral contraceptives (COCs)
C) Progestin-only pill
D) Condoms
Answer
Answer B: . Combined oral contraceptives (COCs)
Rationale
COCs suppress ovarian androgen production and increase sex hormone-binding globulin (SHBG),
reducing free testosterone. They also regulate menstrual cycles and provide contraceptive benefits,
making them first-line therapy for PCOS when pregnancy is not desired. ---
Question 8
8. A 52-year-old woman complains of vulvovaginal dryness, dyspareunia, and urinary urgency.
She is not interested in systemic hormone therapy. What is the most appropriate first-line
treatment for her genitourinary syndrome of menopause?
A) Oral ospemifene
B) Vaginal estrogen therapy
C) Systemic estrogen-progestin therapy
D) Testosterone gel
Answer
Answer B: . Vaginal estrogen therapy
Rationale
Low-dose vaginal estrogen is the most effective treatment for moderate-to-severe genitourinary
syndrome of menopause (GSM). It has minimal systemic absorption and is safe for women who
cannot or choose not to use systemic hormone therapy. ---
